Cepheid, a Danaher company, announced that it has received Emergency Use Listing (EUL) from the World Health Organization (WHO) for the Xpert Hemorrhagic Fever Panel test to support the diagnostic response to the Ebola Bundibugyo (BDBV) outbreak in the Democratic Republic of the Congo (DRC).

The listing enables healthcare providers and public health authorities to leverage Cepheid's rapid molecular testing technology to help identify suspected cases and support timely outbreak containment efforts.

The Xpert Hemorrhagic Fever Panel test detects and identifies nucleic acids of the following viruses: Ebola virus (including Zaire, Sudan, Taï Forest, and Bundibugyo, not differentiated), as well as Crimean-Congo hemorrhagic fever (CCHF) virus, Marburg virus, and Lassa virus. The time to result is about one hour. The assay runs on Cepheid's GeneXpert Dx systems, which are widely deployed across Africa—an established infrastructure that can support rapid implementation of decentralized testing in affected regions.  

IVD. In Vitro Diagnostic Medical Device. Not available in all countries.

Visit Cepheid for more information